Duvakitug not checked

Sanofi · SAR447189 · TEV-48574

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
7 active
9 in total · 7 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
How it’s given
“Pharmaceutical form:Solution for Injection-Route of administration:SC injection”In the company’s words, NCT07184996 on ClinicalTrials.gov
Tested for
Ulcerative Colitis (3 trials), Crohn's Disease (3 trials), Crohn Disease, Colitis, Ulcerative, Hidradenitis
Main trialPhase 3
“This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis (UC). Study details include: The study duration may be up to 35 weeks with: * Screening period * 12-week Sub-Study 1 (Single-Arm Open-Label Feeder Induction) or Sub-Study 2 (Pivotal Induction) * 12-week Sub-Study 3 (Extended Induction for non-responders) * 45 days follow-up visit for participants who do not enroll into the maintenance study (EFC18359) The treatment…”In the company’s words, NCT07184996 on ClinicalTrials.gov
Other names
SAR447189 · TEV-48574

Other drugs for Ulcerative Colitis

All 79 drugs for Ulcerative Colitis

Coming up6

Changes1

Last 90 days

Trials9

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 9 May 2028 An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 3Recruiting 21 Sep 2028 A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 3Recruiting 14 May 2029 An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Phase 3Recruiting 13 Aug 2029 A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Phase 2Active, not recruiting 5 Jan 2026 A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
Phase 2Recruiting 16 Jun 2028 A Study to Investigate Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Phase 1Not yet recruiting 8 Aug 2028 An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
Phase 2Terminated 17 Jan 2022 A Study to Test if TEV-48574 is Effective in Relieving Asthma
Phase 2Completed 12 Nov 2024 A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Duvakitug

Following is part of Solo: you see every change to Duvakitug the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in